SCD Stem Cell Mobilization and Apheresis Using Motixafortide

Clinical Trial
Study Details
Enrollment
20
Interventions
Description

Given Subcutaneously (under the skin).

Name
Motixafortide
Type
Drug
Phase
Phase 1
Status
RECRUITING
Study ID #
NCT06442761
Study Type
Interventional
Summary

This study is being done to see if the study drug, motixafortide, is safe in participants with sickle cell disease (SCD). Investigators also want to see if the drug will help the body increase the number of stem cells that can be collected for possible future transplant use.

PRIMARY OBJECTIVE

* To characterize the safety and tolerability of motixafortide in participants with SCD as determined by the incidence of adverse events (AEs).

SECONDARY OBJECTIVES

* To characterize the efficacy of a single dose (Part A) or two doses (Part B) of motixafortide for hematopoietic stem cell (HSC) mobilization and apheresis collection in participants with SCD as determined by the yield of CD34+ cells (CD34+ cells/kg).
* To measure the mobilization effects of single-day (Part A) or daily dosing (Part B) dosing with motixafortide in the peripheral blood in participants with SCD as determined by peak peripheral blood CD34+ counts
* To recommend a phase 2 dosing strategy based on safety, efficacy, and mobilization effects

Study Overview
Conditions
Description

This study is divided into 2 parts. Participants will be assigned to a part based on when they enroll. Early in the study, participants will be assigned to part A. Later in the study, participants will be assigned to part B. In both parts, participants will receive the study drug, motixafortide, by an injection under the skin. About 8 hours after the injection, stem cells will be collected. Participants will follow-up within 7-10 days after the study drug and stem cell collection. Study staff will contact participants about 30 (±3) days after the last drug dose administration. The follow up may be conducted in person if the participant is in clinic during that follow up period.

Contacts and Locations
Locations
Facility

University of Alabama at Birmingham
Birmingham, Alabama 35294
United States

GeoPoint
33.52066, -86.80249
Status
Recruiting
Facility

National Heart, Blood and Lung Institute-Cellular and Molecular Therapy Branch
Bethesda, Maryland 20814
United States

GeoPoint
38.98067, -77.10026
Status
Recruiting
Facility

St. Jude Children's Research Hospital
Memphis, Tennessee 38105
United States

GeoPoint
35.14953, -90.04898
Status
Recruiting